Citadel Advisors
ICPT

Citadel Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Citadel Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-83,800
Closed -$1.55M – 15661
2023
Q3 		$1.55M Sell
83,800
-58,400
-41% -$661K ﹤0.01% 5693
2023
Q2 		$1.57M Buy
142,200
+300
+0.2% +$4.18K ﹤0.01% 5598
2023
Q1 		$1.91M Buy
141,900
+18,900
+15% +$327K ﹤0.01% 5484
2022
Q4 		$1.52M Sell
123,000
-93,800
-43% -$1.33M ﹤0.01% 6004
2022
Q3 		$3.02M Buy
216,800
+129,900
+149% +$2.09M ﹤0.01% 4794
2022
Q2 		$1.2M Sell
86,900
-83,400
-49% -$1.34M ﹤0.01% 6606
2022
Q1 		$2.77M Buy
170,300
+15,200
+10% +$238K ﹤0.01% 5371
2021
Q4 		$2.53M Buy
155,100
+26,900
+21% +$453K ﹤0.01% 5695
2021
Q3 		$1.9M Sell
128,200
-5,000
-4% -$80K ﹤0.01% 6488
2021
Q2 		$2.66M Buy
133,200
+13,200
+11% +$262K ﹤0.01% 5898
2021
Q1 		$2.77M Sell
120,000
-85,800
-42% -$2.39M ﹤0.01% 5629
2020
Q4 		$5.08M Buy
205,800
+44,900
+28% +$1.49M ﹤0.01% 3657
2020
Q3 		$6.67M Sell
160,900
-44,700
-22% -$2.05M ﹤0.01% 2759
2020
Q2 		$9.85M Buy
205,600
+51,200
+33% +$3.96M ﹤0.01% 2234
2020
Q1 		$9.72M Sell
154,400
-232,800
-60% -$20.9M ﹤0.01% 1886
2019
Q4 		$48M Sell
387,200
-54,800
-12% -$4.91M 0.02% 792
2019
Q3 		$29.3M Buy
442,000
+361,700
+450% +$24.3M 0.01% 1142
2019
Q2 		$6.39M Sell
80,300
-334,600
-81% -$29.9M ﹤0.01% 2746
2019
Q1 		$46.4M Buy
414,900
+295,000
+246% +$32.2M 0.02% 724
2018
Q4 		$12.1M Buy
119,900
+26,300
+28% +$2.73M 0.01% 1694
2018
Q3 		$11.8M Buy
93,600
+33,300
+55% +$3.52M 0.01% 1922
2018
Q2 		$5.06M Sell
60,300
-500
-0.8% -$36.6K ﹤0.01% 2758
2018
Q1 		$3.74M Sell
60,800
-28,300
-32% -$1.71M ﹤0.01% 2830
2017
Q4 		$5.21M Sell
89,100
-3,200
-3% -$202K ﹤0.01% 2434
2017
Q3 		$5.36M Buy
92,300
+73,700
+396% +$7.94M ﹤0.01% 2240
2017
Q2 		$2.25M Sell
18,600
-5,200
-22% -$602K ﹤0.01% 3028
2017
Q1 		$2.69M Sell
23,800
-26,900
-53% -$3.14M ﹤0.01% 2718
2016
Q4 		$5.51M Buy
50,700
+8,500
+20% +$1.01M 0.01% 1901
2016
Q3 		$6.95M Sell
42,200
-11,300
-21% -$1.78M 0.01% 1678
2016
Q2 		$7.63M Sell
53,500
-20,700
-28% -$3.02M 0.01% 1460
2016
Q1 		$9.53M Buy
74,200
+53,700
+262% +$6.34M 0.01% 1233
2015
Q4 		$3.06M Sell
20,500
-2,900
-12% -$491K ﹤0.01% 2308
2015
Q3 		$3.88M Buy
23,400
+2,800
+14% +$616K ﹤0.01% 2202
2015
Q2 		$4.97M Sell
20,600
-34,500
-63% -$9.19M ﹤0.01% 2077
2015
Q1 		$15.5M Buy
55,100
+33,300
+153% +$7.21M 0.01% 1136
2014
Q4 		$3.4M Sell
21,800
-8,400
-28% -$1.55M ﹤0.01% 2350
2014
Q3 		$7.15M Buy
30,200
+5,600
+23% +$1.43M 0.01% 1659
2014
Q2 		$5.82M Sell
24,600
-3,000
-11% -$791K 0.01% 1699
2014
Q1 		$9.1M Buy
+27,600
New +$9.31M 0.01% 1330

Citadel Advisors's ICPT Position: Q4 2023 in Review

Citadel Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 81,972 shares — an estimated $1.52M sold.

Citadel Advisors first reported a position in ICPT in Q1 2014 and held it in 37 quarters. The position peaked at $84.3M in Q2 2019. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.

  • Citadel Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Citadel Advisors sold 81,972 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $1.52M.
  • Citadel Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 37 quarters.
  • Citadel Advisors's Intercept Pharmaceuticals, Inc. position peaked at $84.3M in Q2 2019.
  • 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.